We are looking for an enthusiastic and ambitious PhD candidate to further innovate glycoproteomics technologies and apply these in CDG model systems. CDG is a group of inherited genetic diseases that are characterized by abnormal protein glycosylation. Our research is focused on the identification of new disease genes and on the understanding of protein glycobiology in human disease. In a recently granted Erare project on rare diseases “Euroglycanomics”, eight groups from different countries will collaborate to understand genetic glycosylation disorders by application of –omics technology. The project has a strong translational signature with basic and applied science.
The PhD candidate will collaborate with specialists in our team to further innovate glycomics and glycoproteomics technologies using the newest generation trapped ion mobility time-of-flight mass spectrometer (timsTOF Pro). We have recently established glycopeptide and glycomics methodologies that enable the comprehensive analysis of protein glycobiology in highly complex samples. These methods will be further developed to include ion mobility information and PASEF data acquisition (>100Hz MS/MS acquisition) to study models of defined genetic diseases. These include knock-out cells for specific glycosylation genes and tissue-specific patient derived models (from induced pluripotent stem cells).
- Academic degree (MSc) in molecular life sciences, preferably analytical chemistry;
- Experience with mass spectrometry;
- Enthusiasm and ambition to succeed in academic research;
- Excellent oral and written communication skills.
The experimental research of the department of Neurology is embedded in the Translational Metabolic Laboratory and harbors a range of top researchers in the area of genetic-metabolic disease. The position is within the Glycosylation Disorders group that includes a mass spectrometry and molecular biology section. The research in the lab is closely linked to other departments such as Genetics and Pediatrics. The combined infrastructure is highly innovative including the Radboud Technology Center for mass spectrometry (proteomics, glycomics and metabolomics) with a wide range of analytical equipment and mass spectrometers. In addition, research is performed in model cells and organisms using molecular biology tools to identify and investigate new disease genes.
Radboudumc strives to be a leading developer of sustainable, innovative and affordable healthcare to improve the health and wellbeing of people and society in the Netherlands and beyond. This is the core of our mission: To have a significant impact on healthcare. To get a better picture of what this entails, check out our strategy.